LED therapy plus idebenone treatment targeting calcium and mitochondrial signaling pathways in dystrophic muscle...

Area of Science:

• Biomedical Science
• Cell Biology
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is characterized by intracellular calcium dysregulation, oxidative stress, and mitochondrial dysfunction.
• These cellular impairments significantly contribute to disease progression in DMD.
• The mdx mouse model is widely used to study DMD pathophysiology and test potential therapeutic interventions.

Purpose of the Study:

• To investigate the therapeutic effects of light emitting diode therapy (LEDT) and idebenone on dystrophic muscle cells from mdx mice.
• To evaluate the impact of LEDT and idebenone, applied alone or in combination, on calcium and mitochondrial signaling pathways.
• To assess the safety and efficacy of these treatments by examining cytotoxic effects and key molecular markers.

Main Methods:

• Primary muscle cells were isolated from mdx mice.
• Cells were treated with LEDT and/or idebenone.
• Evaluations included cytotoxicity assays, intracellular calcium content measurements, and analysis of oxidative stress markers (H2O2, 4-HNE).
• Mitochondrial function was assessed via oxygen consumption rate (OCR) and oxidative phosphorylation (OXPHOS) levels.
• Key signaling pathway proteins (calpain-1, calsequestrin, sarcolipin, PGC-1α, SIRT-1, PPARδ) were quantified.

Main Results:

• Neither LEDT nor idebenone exhibited cytotoxic effects on mdx muscle cells.
• Both treatments significantly reduced intracellular calcium, calpain-1, calsequestrin, and sarcolipin levels.
• Oxidative stress markers (H2O2, 4-HNE) were significantly decreased.
• Mitochondrial oxidative capacity (OCR, OXPHOS) and levels of PGC-1α, SIRT-1, and PPARδ were significantly increased.
• Combined LEDT and idebenone treatment demonstrated slightly superior outcomes for sarcolipin, OXPHOS, and SIRT-1 compared to individual treatments.

Conclusions:

• LEDT and idebenone, individually or combined, effectively modulate calcium and mitochondrial signaling pathways in dystrophic muscle cells.
• These modulations, including effects on SLN, SERCA 1, and PGC-1α, suggest a potential improvement in the dystrophic phenotype.
• The combined therapy shows promise as a potential therapeutic strategy for Duchenne muscular dystrophy.